0000899243-18-018332.txt : 20180627 0000899243-18-018332.hdr.sgml : 20180627 20180627163030 ACCESSION NUMBER: 0000899243-18-018332 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180625 FILED AS OF DATE: 20180627 DATE AS OF CHANGE: 20180627 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ZDRAVESKI ZORAN CENTRAL INDEX KEY: 0001741285 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38541 FILM NUMBER: 18922093 MAIL ADDRESS: STREET 1: C/O MAGENTA THERAPEUTICS STREET 2: 50 HAMPSHIRE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Magenta Therapeutics, Inc. CENTRAL INDEX KEY: 0001690585 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 245 FIRST STREET STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 857-201-2700 MAIL ADDRESS: STREET 1: 245 FIRST STREET STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-06-25 0 0001690585 Magenta Therapeutics, Inc. MGTA 0001741285 ZDRAVESKI ZORAN C/O MAGENTA THERAPEUTICS, INC. 50 HAMPSHIRE STREET CAMBRIDGE MA 02139 0 1 0 0 See Remarks Common Stock 2018-06-25 4 C 0 4643 A 140092 D Series C Preferred Stock 2018-06-25 4 C 0 12000 D Common Stock 4643 0 D The Series C Preferred Stock converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Series C Preferred Stock had no expiration date. Secretary and Chief Legal Officer /s/Zoran Zdraveski 2018-06-27